KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Ratio: 2011-2025

Historic Equity Ratio for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to 0.74.

  • Supernus Pharmaceuticals' Equity Ratio fell 1.43% to 0.74 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.74, marking a year-over-year decrease of 1.43%. This contributed to the annual value of 0.76 for FY2024, which is 4.97% up from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Equity Ratio stood at 0.74, which was down 3.93% from 0.77 recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Equity Ratio high stood at 0.77 for Q2 2025, and its period low was 0.48 during Q4 2021.
  • Moreover, its 3-year median value for Equity Ratio was 0.73 (2024), whereas its average is 0.72.
  • Its Equity Ratio has fluctuated over the past 5 years, first fell by 3.36% in 2022, then skyrocketed by 43.30% in 2023.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Equity Ratio stood at 0.48 in 2021, then rose by 7.77% to 0.52 in 2022, then soared by 38.56% to 0.72 in 2023, then increased by 4.97% to 0.76 in 2024, then dropped by 1.43% to 0.74 in 2025.
  • Its Equity Ratio stands at 0.74 for Q3 2025, versus 0.77 for Q2 2025 and 0.77 for Q1 2025.